Patient acceptability of and readiness-to-pay for pharmacy-based health membership plans to improve hypertension outcomes in Lima, Peru

Autor: Daniel A. Antiporta, Yukimi Yshii, Patricia J. García, Elisabeth Vodicka, Joseph R. Zunt

Introduction Pharmacies have been used to improve population health in Peru and other countries globally, operating as a non-traditional health access point. A pharmacy-based model holds potential to improve patient management of hypertension, a lead

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a83ee454433e13dc448b135d2659a162
https://hdl.handle.net/20.500.12866/4717

Cost-effectiveness of psoriasis therapy with etanercept in Germany

Autor: Wolf-Henning Boehncke, Lioba Stratmann, Reinhard Rychlik, Dietmar Daniel, Tatjana Heinen-Kammerer

Publikováno v: Journal der Deutschen Dermatologischen Gesellschaft, Vol. 5, No 9 (2007) pp. 762-768

BACKGROUND: We estimated the cost-effectiveness of intermittent therapy with etanercept in patients with moderate-to-severe plaque-type psoriasis in comparison to non-systemic therapy in Germany. PATIENTS AND METHODS: We performed a cost-utility anal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e132f1e664584b79b93349ce66fe2b5
https://doi.org/10.1111/j.1610-0387.2007.06489.x

Defining catastrophic costs and comparing their importance for adverse tuberculosis outcome with multi-drug resistance: a prospective cohort study, Peru

Autor: Rosario Montoya, Tom Wingfield, Karine Zevallos, Carlton A. Evans, Arquímedes Gavino, Knut Lönnroth, Marco A. Tovar, Delia Boccia

Publikováno v: PLoS Medicine
PLOS MEDICINE
PLoS Medicine, Vol 11, Iss 7, p e1001675 (2014)

Tom Wingfield and colleagues investigate the relationship between catastrophic costs and tuberculosis outcomes for patients receiving free tuberculosis care in Peru. Please see later in the article for the Editors' Summary
Background Even when t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a73c68ce3fc77ace2da1b6aab8760895
https://hdl.handle.net/20.500.12866/8085

Fondaparinux versus enoxaprin in the management of acute coronary syndromes in Switzerland: A cost comparison analysis

Autor: Michel P. Kossovsky, François Mach, Jean-Michel Gaspoz, Pierre Fréderic Keller

Publikováno v: Swiss Medical Weekly, Vol. 142 (2012) P. w13536
Swiss medical weekly

QUESTION UNDER STUDY Anticoagulation therapy is routinely used in cases of non ST segment elevation acute coronary syndromes (NSTE ACS). The most commonly used drug in such events is enoxaparin a low molecular weight heparin. Fondaparinux a synthetic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bedca7637b9c320c608e5b9b61cd08c4
https://archive-ouverte.unige.ch/unige:31879

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

Autor: Daniel Aletaha, Tom W J Huizinga, Ferdinand C. Breedveld, Guido Valesini, Josef S Smolen, Laure Gossec, Maurizio Cutolo, Johannes W. J. Bijlsma, Piet L. C. M. van Riel, Paul Emery, Kevin L. Winthrop, Cécile Gaujoux-Viala, Jackie L Nam, John H. Wong, Tuulikki Sokka, Emilio Martín-Mola, Angela Zink, Simone L Gorter, M. Scholte, Juan J. Gomez-Reino, Ronald F van Vollenhoven, Karel Pavelka, Cem Gabay, David Scott, Maya H Buch, Bernard Combe, Iain B. McInnes, Désirée van der Heijde, Robert Landewé, Monika Schoels, Rachel Knevel, Tore K Kvien, Marios Kouloumas, Gerd-Rüdiger Burmester, Maxime Dougados

Publikováno v: Annals of the Rheumatic Diseases
Scopus-Elsevier
Annals of the Rheumatic Diseases, 69(6), 964-975
Annals of the Rheumatic Diseases, Vol. 69, No 6 (2010) pp. 964-975
Annals of the Rheumatic Diseases, 69(6), 964-975. BMJ Publishing Group
Annals of the Rheumatic Diseases, 69, 964-75
Smolen, J S, Landewé, R, Breedveld, F C, Dougados, M, Emery, P, Gaujoux-Viala, C, Gorter, S, Knevel, R, Nam, J, Schoels, M, Aletaha, D, Buch, M, Gossec, L, Huizinga, T, Bijlsma, J W J W, Burmester, G, Combe, B, Cutolo, M, Gabay, C, Gomez-Reino, J, Kouloumas, M, Kvien, T K, Martin-Mola, E, McInnes, I, Pavelka, K, van Riel, P, Scholte, M, Scott, D L, Sokka, T, Valesini, G, van Vollenhoven, R, Winthrop, K L, Wong, J, Zink, A & van der Heijde, D 2010, ' EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs ', Annals of the rheumatic diseases, vol. 69, no. 6, pp. 964-975 . https://doi.org/10.1136/ard.2009.126532
Annals of the Rheumatic Diseases, 69, 6, pp. 964-75

Contains fulltext : 88773.pdf (Publisher’s version ) (Closed access) Treatment of rheumatoid arthritis (RA) may differ among rheumatologists and currently, clear and consensual international recommendations on RA treatment are not available. In thi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee72196f815546d9501df1e56c3286d7
https://doi.org/10.1136/ard.2009.126532